It was supposed to be a Parkinson's drug.
It failed at that. What the trial teams noticed instead was that people kept losing weight — without being asked to, without diet instructions, without trying. Two decades later tesofensine still carries one of the largest weight-loss numbers ever produced by a tablet, and it is still approved in exactly zero countries.
Both halves of that sentence are load-bearing. This page covers the number everyone quotes, the trial it came from, the formal caution its own journal later attached to that trial, the phase 3 study almost nobody cites, and what the compound does to appetite over six months. That last one is where the popular story falls apart.
🔑 Key Takeaways
- Tesofensine blocks reuptake of dopamine, noradrenaline and serotonin at once — that triple action explains the results and the risks equally.
- The 10.6% figure is real, but it comes from a single phase 2 trial, and what happened to that paper five years later is missing from nearly every page that quotes it.
- A phase 3 trial was completed. Where it ran, which dose it quietly dropped, and why you have never seen it cited are all below.
- The appetite suppression does not hold. The study that tracked it week by week found something the "appetite killer" nickname gets precisely backwards.
- A ten-day half-life changes everything about how side effects appear — and almost nobody explains what that actually means in practice.
- It is a medicine nowhere on earth, yet it sells two ways online, and those two ways carry very different risks.
What Is Tesofensine?
A tablet, not a peptide.
Tesofensine is a triple monoamine reuptake inhibitor — a small molecule taken orally that blocks the reabsorption of dopamine, noradrenaline and serotonin. That single fact separates it from almost everything else in the current weight-loss conversation, where the leading drugs are injectable peptides.
Its regulatory position is simple and often misreported: it is an investigational drug. The FDA has never cleared it for obesity. No European regulator has approved it. A Mexican application exists and remains unresolved. There is no country where a doctor can write you a prescription for it.
From Failed Alzheimer's Drug to Weight-Loss Candidate
It started life as NS2330.
The Danish company NeuroSearch developed it in the 1990s for Parkinson's disease and Alzheimer's, on the reasonable theory that raising dopamine and noradrenaline in the brain might slow decline in both. Partnered development followed. It did not deliver on either indication and was dropped.
The weight loss showed up in that discarded data. Across the Alzheimer's and Parkinson's trial populations, people on 1 mg daily lost around 4 kg over a 14-week treatment period — with no dietary instruction and no weight-loss intent. In those trials, weight loss was logged as an unexpected effect, not an outcome anyone was chasing.
That is an unusual origin for an obesity drug, though not a rare one. Several appetite medicines were discovered the same way, by noticing a side effect worth more than the intended effect.
How Tesofensine Works
Three systems, one tablet.
Nerve cells release neurotransmitters into the gap between them, then pull them back in to be recycled. That pull-back is reuptake. Block it and the signal lingers, continuing to act.
Most drugs block one transporter. An SSRI antidepressant blocks serotonin's. Tesofensine blocks all three — dopamine, noradrenaline and serotonin — which is what "triple monoamine reuptake inhibitor" means, and why its effects are broader and messier than a single-target drug.
What Each Signal Contributes
- Noradrenaline drives classic appetite suppression — the same route phentermine takes, and the source of the dry mouth and insomnia.
- Serotonin contributes to satiation: feeling that a meal was enough, and expecting to eat less at the next one.
- Dopamine is the distinctive one. It acts on wanting rather than fullness — the pull toward food, not the capacity for it.
That dopamine component is what people mean when they say tesofensine quiets food noise rather than simply filling them up. Saniona's chief executive Jørgen Drejer framed the company's own reading of the phase 3 result the same way: "The strong weight loss is driven by tesofensine's ability to reduce appetite and craving for food."
What It Does Not Do to Metabolism
This is worth correcting, because it is widely overstated.
Sjödin and colleagues put 32 overweight and moderately obese men in a respiration chamber and measured energy expenditure directly (International Journal of Obesity, 2010). Participants lost 1.8 kg more than placebo over two weeks and reported clearly higher satiety and fullness.
But on metabolic rate, the finding was narrow: no significant effect on total 24-hour energy expenditure. There was a 4.6% rise during the night period only, and a genuine increase in 24-hour fat oxidation of 18 g. The authors' own conclusion was that tesofensine has a pronounced effect on appetite and a slight effect on energy expenditure at night.
So pages claiming tesofensine "boosts metabolism" are stretching a night-time-only signal into a whole-day claim the study explicitly did not find. The weight loss is an eating story, not a furnace story.
What the Trials Actually Showed
The 2008 Lancet Trial
Every tesofensine number traces here.
Astrup and colleagues published in The Lancet in 2008 (372(9653):1906–13). Phase 2, across five Danish obesity centres: 203 patients with a BMI between 30 and 40, all on an energy-restricted diet, randomised to 0.25 mg, 0.5 mg, 1.0 mg or placebo, once daily for 24 weeks.
The dose-response is orderly, which is part of why it was taken seriously.
Arne Astrup, who led it, told reporters the result was "quite solid from this study that it seems to produce a weight loss that is twice… what we see from existing compounds on the market", and added that "so far there have been no warnings about problematic side effects. It seems clean so far." He went further elsewhere, suggesting that combined with an effective diet "you could probably reach the 20 percent weight loss seen in gastric surgery."
The paper was more restrained than the coverage. Its stated conclusion was that 0.5 mg "might have the potential to produce a weight loss twice that of currently approved drugs" — and that this required confirmation in phase 3.
The dropout numbers nobody reads properly
12% of the 0.5 mg group did not complete. Neither did 29% of the 1.0 mg group. That gap is routinely quoted to argue 0.5 mg is the sensible dose, and it does support that: of those who quit the 1.0 mg arm, 20.4% left because of adverse effects, against roughly 8% elsewhere. Astrup himself said there was "no reason to pursue [1.0 mg] because it doesn't produce much more weight loss, but [it] increases problems."
What gets left out is the third number: 25% of the placebo group also dropped out — nearly as many as the highest dose. That says something about how hard these trials are to retain people in, and it means the completer figures are drawn from a self-selected group in every arm, drug and placebo alike.
Why The Lancet Flagged That Trial
In April 2013, The Lancet published a formal Expression of Concern about the 2008 tesofensine trial (2013;381(9873):1167).
A journal issues one of these when questions about a published paper are serious enough to warn readers, without going as far as retraction. The paper stands. It is still cited. But it carries a permanent flag from the journal that published it.
Why this matters more than it sounds: the concerns centred on trial conduct and on how adverse events were recorded. That is not a footnote for a drug whose entire argument rests on being effective and well tolerated. And it applies to the exact study that produced 9.2% and 10.6% — the two figures repeated on every page selling this compound.
You will not find this mentioned on most of them. Where it does appear, it tends to be described as a routine site inspection rather than a formal journal action, and then waved off.
The skeptic who turned out to be right
Not everyone was swept along in 2008. Ian Broom of Robert Gordon University, commenting at the time, said: "We should therefore be a little circumspect about accepting these claims as to efficacy and await the results of the more relevant Phase III studies, which the author does say at the end of the paper."
Read that with eighteen years of hindsight. He asked for phase 3 before believing the number. Phase 3 eventually happened — in one country, run by the licence holder, and never published. His caution has aged considerably better than the headlines.
The Shorter and Longer Trials
Two others get cited, both weaker in design.
TIPO-2 ran 32 overweight volunteers for 14 days with no diet or exercise changes at all. Mean weight loss was 2.2 kg against 0.4 kg on placebo, with a maximum of 4.7 kg. Short, small, but interesting precisely because nothing else was changed.
TIPO-4 was a 48-week open-label extension, reporting total mean weight loss of 13–14 kg at 24 weeks for those continuing on 0.5 mg. It gets quoted as proof the weight loss is "fully sustained." Open-label means everyone knew what they were taking, there was no placebo control, and the people who stayed in were the ones it was working for. That design cannot support a claim about durability.
VIKING — The Phase 3 Nobody Cites
Confirmation did arrive. It took a decade and happened somewhere most readers never look.
Medix, which licenses tesofensine for Mexico and Argentina, ran a phase 3 registration trial there: 372 patients randomised across three arms for 24 weeks, announced in December 2018. It met primary and secondary endpoints, with roughly 10% average weight loss and more than half of treated patients losing over 10% of body weight, both doses beating placebo at p<0.001.
Two things about it go almost entirely unremarked.
It has never been published in a peer-reviewed journal. Eight years on, what exists publicly is a company press release. No independent reviewer has examined the data. That is not proof of a problem, but it is a conspicuous absence for a trial intended to support a marketing application.
The arms were 0.25 mg and 0.50 mg only. The 1.0 mg dose — the one that produced the famous 10.6%, the number that made tesofensine's reputation — was dropped from the registration programme entirely. The developers themselves declined to carry it forward. Anyone quoting 10.6% at you is quoting a dose the sponsor abandoned.
The Appetite Effect Fades
This is the finding that should reframe the whole thing.
A separate analysis of the same phase 2 programme, published in Obesity in 2012, measured appetite directly rather than inferring it from weight. Participants rated hunger, fullness, satiety and how much they expected to eat, combined into a composite satiety score.
On 1.0 mg, the score rose from 52 at baseline to 64 by week 12. By week 24 it had fallen back to 55 — most of the way to where it started. After withdrawal it sat at 50, slightly below baseline, even though participants were 7.2 kg lighter than when they began. Reintroducing the drug pushed it up again, to 56 by week 60.
Two conclusions follow, and both matter more than the headline percentage.
The appetite suppression is front-loaded. It is strongest early and substantially gone by six months, even while weight continues to fall — so the weight loss in the back half of the trial was running on something other than reduced appetite.
And when you stop, appetite does not settle at a new lower level matched to your new lower weight. It returns to baseline or below. That is exactly the physiology that makes regain so reliable, and it is the single most useful thing to understand before starting.
Calling it an appetite killer describes week 12 accurately. It does not describe week 24, and it says nothing at all about week 25.
Dosage and the 234-Hour Half-Life
Three doses have been formally studied: 0.25 mg, 0.5 mg and 1.0 mg, taken once daily in the morning.
| Dose | Weight loss at 24 wks | Studied in | Dropouts | Practical read |
|---|---|---|---|---|
| 0.25 mg | 4.5% | Phase 2 and phase 3 | — | Lightest load; where most formulations sit |
| 0.5 mg | 9.2% | Phase 2 and phase 3 | 12% | The dose the authors themselves settled on |
| 1.0 mg | 10.6% | Phase 2 only | 29% | Dropped from phase 3 by the developers |
The pattern is hard to miss. The dose that produced the famous number also produced the most dropouts, the most adverse-effect withdrawals, and was then abandoned by the people developing the drug.
What a Ten-Day Half-Life Actually Means
Here is the fact that changes how you should think about dosing, and it gets a single sentence almost everywhere it appears.
Population pharmacokinetic modelling (Lehr et al., British Journal of Clinical Pharmacology, 2007) put tesofensine's half-life at 234 hours — close to ten days. Its major metabolite runs longer still, at 374 hours.
Three practical consequences:
- You do not reach steady state for six to eight weeks. Take the same tablet every morning and the amount in your blood keeps rising for nearly two months before it levels off.
- A side effect appearing in week three may be accumulation, not dose. Nothing changed except the total in your system. People routinely misread this as tolerance running out.
- Stopping does not clear it. After the last tablet the drug is still meaningfully present for over a month. There is no quick off-switch if something goes wrong.
That last point is why the cardiovascular profile below deserves more weight than it usually gets. With a short-acting drug you stop and the problem resolves. Here you stop and wait.
Warning: tesofensine has no approved medical use and no dosing obtainable through a pharmacy anywhere. Everything above is trial data, not a recommendation. The heart rate effect is dose-related, and the long half-life means it cannot be quickly reversed. Speak to a clinician who knows your cardiovascular history before considering it.
Our tesofensine dosage guide covers protocols and cycling in more detail.
Side Effects and Cardiovascular Risk
The common list is consistent across trials: dry mouth, nausea, constipation, hard stools, diarrhoea, insomnia and dizziness. Dry mouth and insomnia are what usually end use — the signature of raised noradrenergic tone, shared with phentermine.
Heart Rate and Blood Pressure
This is the part to take seriously.
In the 2008 trial, heart rate rose by 7.4 beats per minute in the 0.5 mg group — the dose most people actually take, and the one carried into phase 3. Blood pressure was not significantly raised at 0.25 mg or 0.5 mg. At 1.0 mg it was, by a mean of 6.8/5.8 mmHg.
There is a subtler point in the follow-up correspondence. Losing weight normally lowers blood pressure. Compared against the same amount of weight lost through lifestyle change alone, tesofensine appeared to leave blood pressure 4–6 mmHg higher than it should have been. In other words the drug gave back some of the cardiovascular benefit the weight loss was supposed to deliver.
Reviewers at the time noted these increases were mild but might prove clinically significant — explicitly invoking sibutramine, an appetite drug withdrawn worldwide in 2010 after a cardiovascular outcomes trial found excess heart attacks and strokes. Sibutramine's signal also looked mild for years.
Mood and Sleep
At 1.0 mg, anger and hostility increased. At both 0.5 mg and 1.0 mg, confusion did. The highest dose showed the highest frequency of mood change overall.
In fairness to the drug, Astrup's team reported no serious psychiatric reactions — no agitation, panic attacks or mood disorders — even though they enrolled people with a history of anxiety or depression. That is a real reassurance. It sits alongside the fact that adverse-event recording was among the concerns raised about that trial, which is why both belong on the page.
Abuse Potential
Worth reporting fairly, because it is a genuine point in the drug's favour.
Schoedel and colleagues (Clinical Pharmacology & Therapeutics, 2010) tested tesofensine in recreational stimulant users against placebo, D-amphetamine, bupropion and atomoxetine. The effects of tesofensine "were not significantly different from those of placebo" and were lower than D-amphetamine on all primary measures. The authors concluded it is unlikely to be recreationally abused.
For a drug that raises dopamine, that is a meaningfully good result — a consequence of how slowly it enters and leaves the brain.
Who Should Not Take It
Most pages on this compound skip this entirely. They should not.
- Existing high blood pressure or arrhythmia. The heart rate effect is dose-related and, given the half-life, slow to reverse.
- MAOI antidepressants. Combining an MAOI with a triple reuptake inhibitor is a serious interaction.
- SSRIs or SNRIs. Tesofensine blocks serotonin reuptake. Stacking it on another serotonergic drug raises serotonin syndrome risk.
- Stimulant medications. Additive cardiovascular and sleep effects.
- A history of insomnia or anxiety. Both are among the most common effects.
- Pregnancy or breastfeeding. No safety data exists, and the long half-life means exposure persists well after stopping.
Tesomet: Tesofensine Plus Metoprolol
The developers had an answer to the heart rate problem.
Tesomet combines tesofensine with metoprolol, a beta-1 blocker. The logic is direct: if the cardiovascular effect comes from sympathetic activation, block that receptor and keep the appetite effect. It is an unusual approach — adding a second drug to manage the first drug's main liability — but a coherent one.
The human results come from rare-disease populations rather than general obesity:
- Hypothalamic obesity. A randomised trial of 21 patients over 24 weeks reported 6.3% average weight loss, reduced waist circumference, more fat than lean tissue lost, and — the point of the exercise — no heart rate increase.
- Prader-Willi syndrome. A phase 2a study in 18 patients on 0.5 mg daily for three months reported weight loss alongside a significant reduction in hyperphagia, the relentless hunger that defines the condition.
The FDA granted orphan drug designation for both indications in 2021. Then the programme stalled: the phase 2b trials were paused in 2022 for funding reasons, explicitly not for safety or efficacy.
So the combination that solves tesofensine's clearest problem exists, showed promise in small trials, and is currently going nowhere for want of money.
Tesofensine vs GLP-1 Medications
This is the comparison that matters in 2026, and the older guides simply do not make it.
| Tesofensine | GLP-1 drugs | What separates them | |
|---|---|---|---|
| Route | Oral tablet, once daily | Injection, mostly weekly | Tesofensine's one real advantage |
| Mechanism | Brain monoamines — wanting and satiation | Gut hormone signalling — fullness, slowed emptying | Different systems entirely |
| Best result | 10.6% at 24 weeks | 15%+ at 68 weeks for the strongest agents | GLP-1 trials ran longer and went further |
| Evidence | Two trials: one flagged, one unpublished | Large published trials plus cardiovascular outcome data | Not comparable in volume or scrutiny |
| Cardiovascular | Raises heart rate; BP rise at the top dose | Outcome trials showing benefit for some agents | Signals point in opposite directions |
| Approval | None, anywhere | Approved and widely prescribed | The decisive practical difference |
The honest read: tesofensine's appeal is that it is a tablet. Everything else favours the alternative. Where GLP-1 drugs have cardiovascular outcome data showing benefit, tesofensine has a heart rate signal and a withdrawn structural cousin.
If injections are the obstacle, the sensible comparison is with oral GLP-1 options rather than with an unapproved compound. Our guide to GLP-1 medications covers what those actually cost, semaglutide vs tirzepatide compares the two leading agents, and appetite suppressants covers the wider field.
For the other oral appetite drug people weigh this against, see tesofensine vs phentermine, and for the longer GLP-1 comparison specifically, tesofensine for weight loss.
Where Tesofensine Approval Actually Stands
Approved nowhere. That is the whole answer, and it is worth being precise about why the internet says otherwise.
You will find pages stating tesofensine is approved in Mexico, sometimes naming brands like Tesomet, Nupenta or Tesogrial. That is wrong.
What actually happened: Medix submitted a new drug application to COFEPRIS, Mexico's regulator. In February 2023, the COFEPRIS technical committee issued a favourable opinion. That opinion is explicitly non-binding — one step in reviewing a new molecule, neither an authorisation nor a rejection. Following later interaction with the regulator, the company was still revising and resubmitting its dossier.
A favourable technical opinion is not a marketing authorisation. No pharmacy in Mexico dispenses tesofensine on a prescription today.
In the United States the position is simpler: the FDA has never cleared tesofensine for obesity, and no application is pending. Tesomet holds orphan designations for two rare conditions, which is a development incentive rather than an approval.
What this means practically: there is no prescription route anywhere. No pharmacy dispenses it, no clinician can prescribe it, and no regulator has inspected the manufacture of what is sold online. Every safeguard that normally sits between a drug and a patient is absent.
Where to Buy Tesofensine
Two routes exist, and they are not equivalent.
Unlabelled powder from online sellers. No verified identity, no verified dose, no batch certificate, no recourse. At doses measured in fractions of a milligram, a weighing error is both easy and consequential — and with a ten-day half-life, an overdose is not something you can simply wait out.
Formulated low-dose capsules. BioFlow is the version most people encounter: 60 capsules delivering 250 mcg of tesofensine each, alongside taurine and magnesium L-threonate, at $169.97. The advantage over loose powder is that the dose is stated and consistent.
Be clear-eyed about that dose. 250 mcg is 0.25 mg — the lowest of the three trial arms, the one that produced 4.5% over 24 weeks. Not the 10.6% headline, which came from four times that amount at a dose the developers dropped. Anyone pairing a 250 mcg product with the 10.6% figure is quoting a number the bottle cannot deliver.
Before you buy: tesofensine is a medicine nowhere on earth. Its heart rate effect is real, dose-related and slow to reverse. If you are going ahead regardless, tell a clinician who knows your cardiovascular history what you are taking, and start at the bottom.
Frequently Asked Questions
The Verdict
The efficacy signal is real, and for an oral drug it is unusually large. That much is not in dispute.
What it rests on is thinner than the internet suggests: one phase 2 trial carrying a formal Expression of Concern from its own journal, one phase 3 trial that was never peer-reviewed and quietly dropped the famous dose, an appetite effect that measurably fades by month six, and a cardiovascular profile close enough to a withdrawn drug that reviewers named the comparison at the time.
None of that makes it worthless. It makes it investigational — which is exactly what it is, twenty years in. If you are going to take it anyway, do it at the bottom of the dose range, do it with someone monitoring your heart rate, and know that stopping takes a month to mean anything.
References
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet 2008;372(9653):1906–13.
- Expression of concern — effect of tesofensine on bodyweight loss. The Lancet 2013;381(9873):1167.
- Gilbert JA, et al. The effect of tesofensine on appetite sensations. Obesity 2012;20(3):553–61.
- Lehr T, et al. Population pharmacokinetic modelling of NS2330 (tesofensine). Br J Clin Pharmacol 2007;64(1):36–48.
- Sjödin A, et al. The effect of tesofensine on energy metabolism and appetite. Int J Obes 2010;34(11):1634–43.
- Schoedel KA, et al. Subjective and objective effects of tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010;88(1):69–78.
- Perez CI, et al. Tesofensine silences GABAergic hypothalamic neurons. PLoS One 2024;19(4):e0300544.
- Huynh K, et al. Randomized controlled trial of Tesomet in hypothalamic obesity. Eur J Endocrinol 2022;186(6):687–700.
- Kang JG, et al. Phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010;12(10):876–82.
- Saniona — tesofensine development pipeline and regulatory status.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new supplement, medication, or treatment. PeptideDeck may earn a commission from affiliate links at no additional cost to you.